Chronic chagasic miocardiopathy in the Hospital de Clinicas and the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, Paraguay.
DOI:
https://doi.org/10.18004/Keywords:
Trypanosoma cruzi, Chagasic Myocardiopathy, Chagas Diseases, Death Sudden, ParaguayAbstract
This is a cross-sectional descriptive study performed from 2006 to 2009 to determine the prevalence of chronic chagasic myocardiopathy in patients that attended the Hospital de Clínicas and the Instituto de Investigaciones en Ciencias de la Salud. All patients with clinical records were subjected to electrocardiogram (ECG) and ecocardiogram while the epidemiological data were collected using a questionnaire filled in during a direct interview. ELISA was used to detect anti-T. cruzi antibodies and in the positive patients, an indirect immunofluorescence test was also carried out. Being 164 patients positive for T. cruzi antibodies; 43% were women and 57 % men, the age range was from 15 to 86 years old. Of the positive patients,only 90 were analyzed because they had complete information and 32% (29/90) of these presented alterations in the cardiologic evaluations; 60% of them were men and 40% women. Of the surveyed people, 43.3% were from the Central Department, 12.2% from Asunción, 11.1% from the Department of Paraguari, 10% from the Department of San Pedro and 7.8% from the Department of Cordillera. The high prevalence of cardiologic alterations (32%) found is a value close to previously published values. It is very important to continue this study in order to increase the sample size and obtain a larger representativity of the results. Based in these results, we emphasized the necessity of considering chagasic myocardiopathy in the clinical evaluations of the public health taking into account the high percentage of myocardiopathies found and the commitment of national cardiologists to eradicate and prevent this pathology, a common cause of sudden death especially when it is not early detected as it also affects young people in reproductive and working age.
References
1. World Bank, World development report 1993. Investing in health world development indicators. New York Oxford University Press; 1993.
2. World Health Organization. Reducing risks, promoting healthy life. The World Health Report 2000: health systems, improving performance. Geneva; 2000.
3. Schmunis GA. American trypanosomiasis and its impact on public health in the Americas. En: Brener Z, Andrade ZA, Barral-Neto M, editors. Trypanosoma cruzi e Doença de Chagas. Rio de Janeiro: Guanabara Koogan 2000; p. 1-20.
4. Carrasco Guerra R, Bellera GJ, Dipaolo A, Navarro A, Durán D, Molina C, Parada H. Evaluación clínica y factores pronósticos en la miocardiopatía chagásica crónica. Avances Cardiol 1998; 18(5):147-152.
5. Mendoza ED, Rodríguez-Bonfante C, Camacho I, Ramírez J, Perdomo T, Cabrera A, Bonfante-Cabarcos R. Patients suffering dilated chagasic cardiomiopathy or non chagasic cardiopathy show increased levels of tumor necrosis factor alpha. Invest Clin 2005; 46(3): 229-240.
6. Pereira MG. Características da mortalidade urbana por doenca de Chagas, Distrito Federal, Brasil. Bol Of Sanit Panam 1984; 96:213.
7. Cerisola A. Muestreo serológico para la Enfermedad de Chagas en conscriptos de la clase 1951. Rev. Paraguaya de Microbiol 1972; 7:90.
8. Vera de Bilbao N, Rojas de Arias A., Vera VC, Riego A, Tomassone M, Sanabria L. Seroprevalencia de la Enfermedad de Chagas en Conscriptos del Servicio Militar de las Fuerzas Armadas de Paraguay. Clase 1977-1980. Rev Pat Trop 2001; 30(2):183-192.
9. Rosner J, Schinini A, Rovira T, Martínez J, Fresco M, Rojas de Arias A, Ferreira ME, Monzón MI. Cardiac and gastrointestinal morbidity by Trypanosoma cruzi.A study at the Tropical Medicine Unit of I.I.C.S.-U.N.A. Memorias del Instituto de Investigaciones en Ciencias de la Salud. Annual Reports 1990. Proceedings of research on Chagas disease and other infectious diseases, EFACIM-JICA, 14:15-25.
10. Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, Álvarez MG, et al. Indicadores clínicos de progresión de la miocarditis chagásica crónica. Rev Esp Cardiol 2005; 58:1037-44.
11. Sousa AS, Xavier SS, Pereira JB, Roy LO, Alvarenga G, Mallet ALR, et al. Predictive models of moderate or severe systolic dysfunction in Chagas' disease based on clinical, electrocardiographic and radiological data. Rev Bras Eco 2001; 14:63-71.
12. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a simple risk score for predicting mortality in Chagas'heart disease. N Engl J Med. 2006; 355:799-808.
13. Ribeiro ALP, Lombardi F, Sousa MR, Barros MVL, Porta A, Barros VCV, et al. Power-law behavior of heart rate variability in Chagas' disease. Am J Cardiol. 2002; 89:414-8.
14. Rassi A Jr, Rassi AG, Rassi SG, Rassi C Jr, Rassi A. Frequência e grau de extra-sistolia ventricular à eletrocardiografia dinámica (sistema Holter de 24 horas) na doença de Chagas. Arq Bras Cardiol 1991; 57 Suppl C:C134.
15. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection. N Engl J Med 1992; 327: 685-91.
16. Mitelman JE, Jiménez L. Miocardiopatía Chagásica Un Enfoque Actual. Edición 1ra. Bs. As. Editorial Interamericana, 2008.
17. Segundo Informe del Comité de Expertos sobre control de la Enfermedad de Chagas, Serie de Informes Técnicos 905. Geneva: OMS 2003; p. 74, 75 y 92.
18. Barretto, AC, Ianni, BM. The undetermined form of Chagas' heart disease: concept and forensic implications. Sao Paulo Med J 1995; 113:797.
19. Bern, C, Montgomery, SP, Herwaldt, BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.
20. Mady C, Cardosos RHA, Barretto ACP et al. Survival and predictors of survival in patients with congestive heart failure due to Chagas'cardiomyopathy. Circulation 1994; 90:3098.
21. Acquatella, H, Catalioti F, Gomez-Mancebo JR et al. Long-term control of Chagas disease in Venezuela: effects on serologic findings, electrocardiographic abnormalities, and clinical outcome. Circulation 1987; 76:556.
22. Laranja FS, Dias E, Nóbrega GC, Miranda A. Chagas disease. A clinical,epidemiological and pathologic study. Circulation 2004;14:1035-1060.
23. Espinosa R, Perici L, Carrasco HA, Escalante A, Martínez O, Gonzalez R. Prognostic indicators in chronic chagasic cardiopathy. Intl J Cardiol 1991; 30:195-202.
24. Hulley S, Cummings S, Browner W, Grady D, Heartst N, Newman T. Designing Clinical Research, Second Edition. Philadelphia, Lippincot Williams & Wilkins 2001. p 91.
25. Kaspar P, Velázquez G, Monzón M, Meza T, Vera M, Pozzoli L, Guillén I, Merlo R, Samudio M, Rodríguez A. Evaluation on a new anti-T. cruzi antibody ELISA kit. Mem Inst Oswaldo Cruz 1988; 83:125.
26. Camargo M. Fluorescent antibody test for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved cultured forms of T. cruzi in a slide test. Rev Inst Med Trop Sao Paulo 1966; 8:227-269.
27. Salles, X.; Silvestre de Sousa, A.; Hasslocher-Moreno, A. Application of the new classification of cardiac insufficiency (ACC/AHA) in Chronic Chagas cardiopathy: A critical analysis of the survival curves. FIOCRUZ, Universidade Federal do Rio de Janeiro, Rev. SOCERJ 2005.
28. Arias A, Rojas D y Col: Seroepidemiología de la Enfermedad de CHAGAS en localidades del Paraguay. Bol Ofic Sanit Panam 1984; 96(3):189 – 197.
29. Arrúa Torreani NR. Cardiopatía Chagásica Crónica. Estudio Comparativo en un medio rural y un medio intrahospitalario. ICM. Universidad Nacional de Asunción, Facultad de Medicina, Tesis Doctoral 1986
30. Consejo de Enfermedad de Chagas y Miocardiopatías Infecciosas Dr. Salvador Mazza. Jornada de Actualización de la Clasificación Clínica de la Enfermedad de Chagas. Rev Col Argent Cardiol 1998; 3:26-27.
31. Acosta N, Samudio M, López E, Vargas F, Yaksic N, Brenière SF, Rojas de Arias A.. Isoenzyme profiles of Trypanosoma cruzi stocks from different areas of Paraguay. Mem Inst Oswaldo Cruz. 2001 May;96(4):527-33.
32. Yeo M, Acosta N, Llewellyn M, Sánchez H, Adamson S, Miles GA, López E, González N, Patterson JS, Gaunt MW, de Arias AR, Miles MA. Origins of Chagas disease: Didelphis species are natural hosts of Trypanosoma cruzi I and armadillos hosts of Trypanosoma cruzi II, including hybrids. Int J Parasitol. 2005 Feb;35(2):225-33. Epub 2004 Dec 22
33. Freitas JM, Lages-Silva E, Crema E, Pena SD, Macedo AM. Real time PCR strategy for the Identification of major lineages of Trypanosoma cruzi directly in chronically infected human tissues. Int J Parasitol. 2005; 35:411–417.
34. Venegas J, Coñoepan W, Pichuantes S, Miranda S, Apt W, Arribada A, Zulantay I, Coronado X, Rodriguez J, Reyes E, Solari A, Sanchez G. Differential distribution of Trypanosoma cruzi clones in human chronic chagasic cardiopathic and non-cardiopathic individuals. Acta Trop. 2009 Mar;109(3):187-93. Epub 2008 Nov 20.
35. Rodríguez Coura JR, De Abreu LL, Pereira JB, Willcox H.P. Morbidade da doenca de Chagas IV Estudio longitudinal de dez anos em Pains e Iguatama Minas Gerais, Brasil. Mem Inst O Cruz 1985; 80:73-80.
36. Madoery RJ, Dománico A, Marcelino A, Madoery C. Alteraciones electrocardiográficas durante el período intermedio, latente o indeterminado de la Enfermedad de Chagas: consideraciones evolutivas. Rev Lat Cardiol 1992; 13:55-59.
37. Rojas de Arias A.Chagas disease in Paraguay.PAHO/HCP/HCT/72/96
38. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a simple risk score for predicting mortality in Chagas'heart disease. N Engl J Med. 2006; 355:799- 808.
39. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001; 76:75- 96.
40. World Bank, World Development Report 1993, Oxford University Press, 1993; p. 216-218.
